Assembly Biosciences (NASDAQ:ASMB) Rating Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

Several other research firms have also recently weighed in on ASMB. BidaskClub cut shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a report on Monday, June 24th. William Blair reissued an outperform rating on shares of Assembly Biosciences in a report on Friday, May 10th. Finally, Chardan Capital reissued a hold rating on shares of Assembly Biosciences in a report on Sunday, June 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Assembly Biosciences has a consensus rating of Hold and a consensus price target of $41.20.

ASMB opened at $13.38 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.97 and a quick ratio of 7.97. The firm’s 50 day moving average is $14.35. Assembly Biosciences has a twelve month low of $12.75 and a twelve month high of $44.65.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The firm had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.81 million. As a group, research analysts predict that Assembly Biosciences will post -4.34 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in shares of Assembly Biosciences by 17.0% during the fourth quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Assembly Biosciences by 87,340.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 4,367 shares during the period. Marshall Wace North America L.P. grew its position in Assembly Biosciences by 191.5% during the first quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 2,911 shares during the period. Metropolitan Life Insurance Co. NY grew its position in Assembly Biosciences by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 5,524 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Assembly Biosciences during the fourth quarter valued at approximately $336,000. 86.44% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Read More: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply